Merus NV (MRUS)
45.49
+1.14
(+2.56%)
USD |
NASDAQ |
Nov 22, 16:00
45.50
+0.01
(+0.02%)
After-Hours: 20:00
Merus Total Liabilities (Quarterly): 141.42M for Sept. 30, 2024
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 141.42M |
| June 30, 2024 | 145.46M |
| March 31, 2024 | 148.64M |
| December 31, 2023 | 99.15M |
| September 30, 2023 | 98.80M |
| June 30, 2023 | 106.22M |
| March 31, 2023 | 121.00M |
| December 31, 2022 | 129.49M |
| September 30, 2022 | 116.21M |
| June 30, 2022 | 118.18M |
| March 31, 2022 | 120.03M |
| December 31, 2021 | 140.40M |
| September 30, 2021 | 150.16M |
| June 30, 2021 | 160.50M |
| March 31, 2021 | 161.41M |
| December 31, 2020 | 128.95M |
| September 30, 2020 | 128.99M |
| June 30, 2020 | 123.36M |
| March 31, 2020 | 123.38M |
| December 31, 2019 | 132.08M |
| Date | Value |
|---|---|
| September 30, 2019 | 130.73M |
| June 30, 2019 | 141.13M |
| March 31, 2019 | 140.86M |
| December 31, 2018 | 147.12M |
| September 30, 2018 | 162.39M |
| June 30, 2018 | 160.81M |
| March 31, 2018 | 171.03M |
| December 31, 2017 | 168.21M |
| September 30, 2017 | 174.01M |
| June 30, 2017 | 172.59M |
| March 31, 2017 | 159.88M |
| December 31, 2016 | 40.26M |
| September 30, 2016 | 5.902M |
| June 30, 2016 | 5.844M |
| March 31, 2016 | 6.289M |
| December 31, 2015 | 7.863M |
| September 30, 2015 | 7.981M |
| June 30, 2015 | 17.97M |
| December 31, 2014 | 8.632M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
98.80M
Minimum
Sep 2023
161.41M
Maximum
Mar 2021
129.69M
Average
128.97M
Median
Total Liabilities (Quarterly) Benchmarks
| Qiagen NV | 2.740B |
| uniQure NV | 589.98M |
| ProQR Therapeutics NV | 91.44M |
| argenx SE | -- |
| Pharming Group | 199.72M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 844.68M |
| Shareholders Equity (Quarterly) | 703.26M |
| Current Ratio | 8.320 |